Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin

ClinicalTrials.gov ID: NCT06323161

Public ClinicalTrials.gov record NCT06323161. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 9:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg Once Weekly Versus Placebo in Participants With Type 2 Diabetes as Add on to Once-daily Basal Insulin With or Without Metformin

Study identification

NCT ID
NCT06323161
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
274 participants

Conditions and interventions

Interventions

  • Cagrilintide Drug
  • Placebo Drug
  • Semaglutide Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 25, 2024
Primary completion
Sep 8, 2025
Completion
Oct 22, 2025
Last update posted
Nov 27, 2025

2024 – 2025

United States locations

U.S. sites
14
U.S. states
11
U.S. cities
13
Facility City State ZIP Site status
Valley Clinical Trials, Inc. Northridge California 91325
Bioclinical Research Alliance Miami Florida 33155
Solaris Clinical Research Meridian Idaho 83646
Iowa Diab & Endo Res Center West Des Moines Iowa 50266
Alliance for Multispec Res Newton Kansas 67114
Elite Research Center Flint Michigan 48532
Palm Research Center Inc. Las Vegas Nevada 89128
University of North Carolina Chapel Hill North Carolina 27614
Clinical Research Associates Nashville Tennessee 37203
Velocity Clinical Res-Dallas Dallas Texas 75230
Synergy Groups Medical Houston Texas 77061
PlanIt Research, PLLC Houston Texas 77079
Manassas Clinical Research Center Manassas Virginia 20110
TPMG Clinical Research Newport News Virginia 23606

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06323161, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 27, 2025 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06323161 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →